Recursion Pharmaceuticals (RXRX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Recursion Pharmaceuticals (RXRX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
.00 on the NASDAQ. This SniperIQ fundamentals page covers Recursion Pharmaceuticals's valuation, profitability (net margin -844.5%), revenue ($75M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Recursion Pharmaceuticals's market cap?
Recursion Pharmaceuticals (RXRX) has a market capitalization of approximately
.00 on the NASDAQ. Market cap moves with the live share price.What is Recursion Pharmaceuticals's P/E ratio?
Recursion Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Recursion Pharmaceuticals?
Recursion Pharmaceuticals runs a net profit margin of -844.5%, a gross margin of -34.4%, and an operating margin of -882.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Recursion Pharmaceuticals generate?
Recursion Pharmaceuticals reported revenue of $75M for fiscal year 2025, with net income of -$645M and earnings per share (EPS) of -1.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Recursion Pharmaceuticals pay a dividend?
Recursion Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Recursion Pharmaceuticals financially healthy?
Recursion Pharmaceuticals carries a debt-to-equity ratio of 0.07x and a current ratio of 5.47x, with a market beta of 0.99. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Recursion Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Recursion Pharmaceuticals (RXRX) the key facts are: market cap
Track Recursion Pharmaceuticals's full fundamentals live
Get Recursion Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.